Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Revlimid® (lenalidomide) – Expanded indication
February 22, 2017 – The FDA approved Celgene’s Revlimid (lenalidomide) for multiple myeloma (MM), as maintenance treatment following autologous hematopoietic stem cell transplantation (auto-HSCT).
